Pacira BioSciences (PCRX) EPS (Diluted) Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 50.12% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 6.26% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -70.43% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.24% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.96% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 64.19% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -18.62% |
| 10 | Pacira BioSciences | 1.05 Bn | 846.97 Mn | 140.96 Mn | 29.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.42% |
| Dec 31, 2025 | 29.41% |
| Sep 30, 2025 | 116.02% |
| Jun 30, 2025 | -31.65% |
| Mar 31, 2025 | -11.07% |
| Dec 31, 2024 | 71.96% |
| Sep 30, 2024 | -115.48% |
| Jun 30, 2024 | -3.71% |
| Mar 31, 2024 | -8.50% |
| Dec 31, 2023 | 12.89% |
| Sep 30, 2023 | 148.48% |
| Jun 30, 2023 | 155.79% |
| Mar 31, 2023 | -90.43% |
| Dec 31, 2022 | -22.44% |
| Sep 30, 2022 | 56.44% |
| Jun 30, 2022 | 88.62% |
| Mar 31, 2022 | 90.21% |
| Dec 31, 2021 | -342.73% |
| Sep 30, 2021 | 145.87% |
| Jun 30, 2021 | 378.73% |